Autologous hematopoietic stem cell transplantation in combination with immunoablative protocol in secondary progressive multiple sclerosis – A 10-year follow-up of the first transplanted patient
Abstract
Introduction. Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system that affects young individuals and leads to severe disability. High dose immunoablation followed by autologous hemopoietic stem cell transplantation (AHSCT) has been considered in the last 15 years as potentialy effective therapeutic approach for agressive MS. The most recent long-time follow-up results suggest that AHSCT is not only effective for highly aggressive MS, but for relapsing-remitting MS as well, providing long-term remission, or maybe even cure. We presented a 10-year follow-up of the first MS patient being treated by immunoablation therapy and AHSCT. Case report. A 27-year-old male experienced the first symptoms - intermitent numbness and paresthesia of arms and legs of what was treated for two years by psychiatrist as anxiety disorder. After he developed severe paraparesis he was admitted to the Neurology Clinic and diagnosed with MS. Our patient developed aggressive MS with frequent relapses, rapid disability progression and transition to secondary progressive form 6 years after MS onset [the Expanded Disability Status Scale (EDSS) 7.0 Ambulation Index (AI) 7]. AHSCT was performed, cyclophosphamide was used for hemopoietic stem cell mobilization and the BEAM protocol was used as conditionig regimen. No major adverse events followed the AHSCT. Neurological impairment improved, EDSS 6.5, AI 6 and during a 10-year follow-up remained unchanged. Brain MRI follow-up showed the absence of gadolinium enhancing lesions and a mild progression of brain atrophy. Conclusion. The patient with rapidly evolving, aggressive, noninflammatory MS initialy improved and remained stable, without disability progression for 10 years, after AHSCT. This kind of treatment should be considered in aggressive MS, or in disease modifying treatment nonresponsive MS patients, since appropriately timed AHSCT treatment may not only prevent disability progression but reduce the achieved level of disability, as well.
References
Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, et al. Association between use of interferon beta and pro-gression of disability in patients with relapsing-remitting mul-tiple sclerosis. JAMA 2012; 308(3): 247−56.
Mancardi GL, Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol 2008; 7(7): 626−36.
Burman J, Iacobaeus E, Svenningsson A, Lycke J, Gunnarsson M, Nilsson P, et al. Autologous haematopoietic stem cell transplan-tation for aggressive multiple sclerosis: the Swedish experience. J Neurol Neurosurg Psychiatry 2014; 85(10): 1116−21.
Burt RK, Balabanov R, Han X, Sharrack B, Morgan A, Quigley K, et al. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with re-lapsing-remitting multiple sclerosis. JAMA 2015; 313(3): 275−84
Comi G, Kappos L, Clanet M, Ebers G, Fassas A, Fazekas F, et al. Guidelines for autologous blood and marrow stem cell trans-plantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Trans-plantation and the European Charcot Foundation. BMT-MS Study group J Neurol 2000; 247(5): 376−82.
Obradović D, Balint B, Dincić E, Raicević R, Obradovidć S, Toncev G, et al. Stem cells use in the treatment of neurologic disorders - has the future already arrived? Vojnosanit Pregl 2008; 65(6): 473−80. (Serbian)
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diag-nosis of multiple sclerosis. Ann Neurol 2001; 50(1): 121–7.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33(11): 1444–52.
Hauser SL, Dawson DM, Lehrich JR, Beal MF, Kevy SV, Propper RD, et al. Intensive immunosuppression in progressive multi-ple sclerosis. A randomized, thre earm study of high-dose in-travenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983; 308(4): 173−80.
Nicholl CR, Lincoln NB, Francis VM, Stephan TF. Assessing quality of life in people with multiple sclerosis. Disabil Rehabil 2001; 23(14): 597−603.
Balint B, Ivanovic Z, Petakov M, Taseski J, Jovcic G, Stojanovic N, et al. The cryopreservation protocol optimal for progenitor re-covery is not optimal for preservation of marrow repopulating ability. Bone Marrow Transpl 1999; 23(6): 613–9.
Krasulova E, Trneny M, Kozak T, Vackova B, Pohlreich D, Kemlink D, et al. High-dose immunoablation with autologous haema-topoietic stem cell transplantation in aggressive multiple scle-rosis: a single centre 10-year experience. Mult Scler 2010; 16(6): 685–93.
Fassas A, Kimiskidis VK, Sakellari I, Kapinas K, Anagnostopoulos A, Tsimourtou V, et al. Long-term results of stem cell transplan-tation for MS: a single-center experience. Neurology 2011; 76(12): 1066–70.
Mancardi GL, Sormani MP, Di Gioia M, Vuolo L, Gualandi F, Amato MP, et al. Italian BMT Study Group. Autologous haem-atopoietic stem cell transplantation with an intermediate inten-sity conditioning regimen in multiple sclerosis: the Italian mul-ti-centre experience. Mult Scler 2012; 18(6): 835−42.
Shevchenko JL, Kuznetsov AN, Ionova TI, Melnichenko VY, Fe-dorenko DA, Kartashov AV, et al. Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis. Exp Hematol 2012; 40(11): 892–8.
Rocca MA, Mondria T, Valsasina P, Sormani MP, Flach ZH, Te Boekhorst PA, et al. A three-year study of brain atrophy after autologous hematopoietic stem cell transplantation in rapidly evolving secondary progressive multiple sclerosis. AJNR Am J Neuroradiol 2007; 28(9): 1659−61.